Biotechnology Equity
Pictet-Biotech
Last updated: 2026-09-09
The Verdict
Pictet-Biotech charges an expense ratio of 1.99%. On a $100,000 portfolio, that's $1,987 per year in fees, and it scales with the amount invested. Supreme.PM's decoded model tracked it at only 41% correlation over the measured period, so it should not be treated as a substitute for this fund, for a flat monthly subscription that does not change with portfolio size.
Expense Ratio
1.99%
Star Rating
1/ 5
Market Beta
0.84
Model Correlation
41%
Sharpe Ratio
0.25
Max Drawdown
39.13%
Supreme.PM Cost
Flat monthly subscription
Not a percentage of your assets
Performance
Performance comparison — 1Y: Fund 35.1% vs Model 28.7%; 3Y: Fund 67.1% vs Model 68.7%; 5Y: Fund 34.3% vs Model 37.4%.
Alpha After Fees
Supreme.PM's model shows 41% correlation with Pictet-Biotech over the measured period. That is weak tracking: the model does not reproduce this fund's return pattern, and a negative figure means it moved in the opposite direction.
Fee Analysis
Pictet-Biotech charges 1.99% of assets annually. Supreme.PM charges a flat monthly subscription instead, so its cost does not rise as a portfolio grows.
Data sources: Refinitiv Lipper, SEC EDGAR Filings, Supreme.PM Analytics
Past performance does not guarantee future results. Model returns are backtested and may not reflect actual trading conditions.
Related
Biotechnology Equity Category
Browse all Biotechnology Equity funds
Biotechnology Equity Rankings
Top-rated Biotechnology Equity funds
Our Methodology
How we decode fund strategies
Candriam Equities Biotechnology
3-star rated
AXA Framlington Biotech
1-star rated
Polar Capital Biotechnology
5-star rated
International Biotechnology Trust
Frequently Asked Questions
What is the expense ratio of Pictet-Biotech?
Pictet-Biotech has an expense ratio of 1.99%, charged as a percentage of the amount invested. Supreme.PM's decoded model is offered for a flat monthly subscription instead.
How does Supreme.PM replicate Pictet-Biotech?
Supreme.PM builds a transparent, rules-based model of listed securities designed to track this fund's return profile. Over the measured period it tracked the fund poorly, at 41% correlation. The model is published in full, so its positions are visible rather than disclosed with a delay.
What are the risks of fund replication?
While our models aim for high correlation, they may not perfectly match the fund's returns due to timing differences in rebalancing, transaction costs, and disclosure delays. Backtested results may not reflect future performance.
Get This Strategy
Start investing with Supreme.PM's decoded model and save on fees while capturing similar returns.